BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Wenn Sun

Session 4 – Data-driven Precision Health

Date:21 July (Wednesday)
Time:  15:40 – 17:10 (GMT+8)

Wenn Sun

Founder and Chief Executive Officer
Precision Medicine Asia Co., Ltd. (PREMIA)


Dr. Sun founded PREMIA in 2018 in collaboration with LC-SCRUM Japan leadership. Previously, Dr. Sun was the Founder and Managing Partner for OxOnc Development, a venture company that, along with Pfizer Oncology, co-developed Xalkori in patients with ROS1 genetic alterations.  Dr. Sun was the head of Strategic Alliances for GSK Oncology, and helped build its alliances with various clinical research networks worldwide.  She was appointed the Chief Business Development officer at the Lurie Cancer Center of Northwestern University after her post-doctoral fellowship at University of Wisconsin-Madison.

Speech title & Synopsis

Building an Integrated Platform for Novel Targeted Therapies and Diagnostic Development

PREMIA manage Japan’s nation-wide, clinical-genomic lung cancer registry (LC-SCRUM) which is a network of 265+ hospitals in Japan and Taiwan.  The LC-SCRUM registry has more than 7,000 patients and provides an efficient patient identification process for clinical trial enrollment.  Before the end of 2021, PREMIA anticipate expanding the registry to Southeast Asian countries.